• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 13, 2014

View Archived Issues

FDA approves Gilead's HCV combo, Harvoni; offers eight-week treatment potential

Gilead Sciences Inc. won FDA approval to market Harvoni, the first oral therapy for people with genotype 1 hepatitis C virus (HCV) to eliminate the need for both interferon and ribavirin. Read More

PTC's nonsense therapy not lost in 'Translarna': Offering raises $108M

With a global, confirmatory phase III trial under way as of June with Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF), plus a phase III experiment in nonsense mutation Duchenne muscular dystrophy (nmDMD) fully enrolled as of last month, PTC Therapeutics Inc. is raising $108.75 million through the sale of 3 million shares at $36.25 each. Read More

Health experts: Say no to randomized trials testing Ebola drugs

LONDON – Leading health experts said that having decided it is ethical to use non-approved products to help deal with the Ebola virus epidemic, it would be unethical if those drugs were administered in the context of randomized clinical trials. Read More

Different disease genes can converge on same biology

Understanding the genetic causes of diseases has allowed a better understanding what, from a cell biological perspective, is going wrong. "We're always defining things genetically, and that is something I subscribe to," Carl Ernst told BioWorld Today. Read More

Into the fray: NIH offers grantees tools to succeed in business

Scientists committed to making a successful leap from lab to market are getting a leg up from a unique NIH pilot program teaching a relatively new model of entrepreneurship, that of the lean start-up. Read More

Oxford Biomedica signs Novartis to $104M deal for CAR T-cell therapies

LONDON – Novartis AG is looking to the commercialization of its CAR T-cell cancer immunotherapies in a $104 million-plus royalties manufacturing deal with Oxford Biomedica plc, to use the gene therapy specialist's Lentivector technology to transfect patients' T cells. Read More

Other news to note

Ariad Pharmaceuticals Inc., of Cambridge, Mass., said the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA concluded its review of Iclusig (ponatinib) and has recommended that the drug continue to be used in Europe in accordance with its already approved indications for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia who are resistant to Sprycel (dasatinib. Read More

Stock movers

Read More

In the clinic

Isis Pharmaceuticals Inc., of Carlsbad, Calif., updated data from its ongoing open-label phase II studies testing ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the International World Muscle Society Congress in Berlin. Read More

Pharma: Other news to note

Janssen-Cilag International NV, of Beerse, Belgium, a unit of Johnson & Johnson, said a type II variation was filed with the EMA seeking approval of Stelara (ustekinuab) for the treatment of moderate to severe plaque psoriasis in pediatric patients, ages 12 to 17, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Read More

Pharma: In the clinic

Ipsen SA, of Paris, reported positive results at the European Association of Urology Central European Meeting in Cracow, Poland, from the phase III study of tritorelin pamoate administered subcutaneously in patients with locally advanced or metastatic prostate cancer. Read More

Bench Press: BioWorld looks at translational medicine

Muscle weakness is a common problem in aging, affecting more than half of individuals older than 80. Now, scientists from Columbia University have shown they were able to improve skeletal muscle function and increase exercise in aged mice by increasing the activity of an antioxidant enzyme specifically in the mitochondria, the energy powerhouses of the cell. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 14, 2025.
  • Circode executives

    Circode applies circRNA to heart disease drug R&D, in vivo CAR T

    BioWorld
    Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...
  • Merger-arrows-black-white.png

    BD’s biosciences & diagnostics unit in $17.5B merger with Waters

    BioWorld MedTech
    Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe